How are energy investors positioned?
Dawn Christine Maroney, the President of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently executed a significant stock sale. On March 6, Maroney sold 278,917 shares of common stock, generating approximately $4.3 million. The shares were sold at a weighted-average price of $15.53 per share, with individual transactions ranging between $15.12 and $16.065 per share. The sale comes as ALHC trades near its 52-week high of $16.25, having delivered an impressive 183% return over the past year. InvestingPro analysis shows the stock is currently fairly valued, with additional insights available in the comprehensive Pro Research Report.
This transaction was prompted by the need to cover tax withholding obligations related to the vesting of performance share units (PSUs). These PSUs were awarded based on the company’s performance metrics, including health plan revenue growth and adjusted EBITDA, which exceeded specified targets. The strong performance is reflected in ALHC’s remarkable 48% revenue growth over the last twelve months, despite operating with moderate debt levels. The acquisition of 1,020,442 shares on March 4 was part of this vesting process, with half of the PSUs becoming fully vested on the acquisition date and the remaining half scheduled to vest on December 31, 2025, contingent on Maroney’s continued service to the company. For deeper insights into ALHC’s financial health and growth prospects, access the full suite of metrics on InvestingPro.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. Full-year 2024 revenue was reported at $2.7 billion, marking a 48% increase year-over-year. Alignment Healthcare achieved its first year of adjusted EBITDA profitability, a significant milestone for the company. Looking ahead, the company has provided guidance for 2025, forecasting revenue between $3.72 billion and $3.78 billion and adjusted gross profit to range from $415 million to $445 million.
In addition to the earnings report, Raymond (NSE:RYMD) James analyst John Ransom increased the price target for Alignment Healthcare to $19.00, citing the company’s robust performance in the fourth quarter. Piper Sandler also raised its price target to $21.00, maintaining an Overweight rating and expressing confidence in Alignment Healthcare’s strategies for growth. Both firms highlighted the company’s ability to scale its business model and deliver consistent, competitive, and cost-effective products across different markets. These developments reflect a promising outlook for Alignment Healthcare, as noted by analysts from both Raymond James and Piper Sandler.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.